Evidence map›Paper›PMID 38819323›Full record

ArticleThe Journal of infectious diseases2025

Drug Resistance and Epidemiological Success of Modern Mycobacterium tuberculosis Lineages in Western India.

Avika Dixit, Yasha Ektefaie, Anju Kagal, Luca Freschi, Rajesh Karyakarte, Rahul Lokhande, Matthias Groschel, Jeffrey A Tornheim, Nikhil Gupte, Neeta N Pradhan and 9 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Gene conversion is a key driver of diversity hotspots inbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Avika DixitDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Yasha EktefaieDivision of Infectious Diseases, Boston Children's Hospital, Boston, Massachusetts, USA.
Anju KagalByramjee-Jeejeebhoy Government Medical College, Pune, India.
Luca FreschiDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Rajesh KaryakarteByramjee-Jeejeebhoy Government Medical College, Pune, India.
Rahul LokhandeByramjee-Jeejeebhoy Government Medical College, Pune, India.
Matthias GroschelDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.
Jeffrey A TornheimCenter for Clinical Global Health Education, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Nikhil GupteCenter for Clinical Global Health Education, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Neeta N PradhanByramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Trials Unit, Pune, India.
Mandar S ParadkarByramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Trials Unit, Pune, India.
Sona DeshmukhByramjee-Jeejeebhoy Medical College-Johns Hopkins University Clinical Trials Unit, Pune, India.
Dileep KadamByramjee-Jeejeebhoy Government Medical College, Pune, India.
Marco SchitoCritical Path Institute, Tucson, Arizona, USA.
David M EngelthalerTranslational Genomics Research Institute, Flagstaff, Arizona, USA.
Amita GuptaCenter for Clinical Global Health Education, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-7036-2718
Jonathan GolubCenter for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Vidya MaveCenter for Clinical Global Health Education, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-8509-4517
Maha FarhatDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3871-5760

Funding

The Johns Hopkins Baltimore-Washington-India Clinical Trials Unit (BWI CTU)UM1AI069465 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Charles W. Flexner, Amita Gupta · 2012 to 2026
$34.1M
Training Program in Bioinformatics and Integrative GenomicsT32HG002295 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Peter J Park · 2001 to 2026
$15.8M
Whole Genome Sequencing of Drug Resistant Tuberculosis in India: Genotype-Phenotype Correlation, Clinical Impact of Resistance, and Sequencing Directly from SputumK23AI135102 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TORNHEIM, JEFFREY · 2018 to 2021
$776k
A novel "shock and kill" strategy for eliminating Mtb persisters in the CD4 T-cell-deficient hostR21AI122922 · NIAID · JOHNS HOPKINS UNIVERSITY · PI KARAKOUSIS, PETROS C · 2016 to 2017
$446k
Adah F. Hall Charity FundBoston Children's Hospital OFDBTRECBushrod H. CampbellBWI CTU NIAID UM1AI069465Charles A. King Trust Postdoctoral FellowshipCTREC Faculty Career Development FellowshipGates Foundation OPP1115887German Research Foundation GR5643/1-1Indian Department of BiotechnologyIndo-US Medical Partnership USB1-31147-XX-13National Institute of Allergy and Infectious Diseases K23AI135102NHGRI NIH HHS T32 HG002295NIAID NIH HHS K23 AI135102NIAID NIH HHS R21 AI122922NIAID NIH HHS UM1 AI069465NIH HHS R01 AI55765RePORT India consortiumReSeqTB sequencing platformThe Impact of Diabetes on TB Treatment Outcomes R01A1097494US Civilian Research and Development Foundation (CRDF)US CRDF OISE-17-63221
6 · The paper itself

Abstract

backgroundDrivers of tuberculosis (TB) transmission in India, the country estimated to carry a quarter of the world's burden, are not well studied. We conducted a genomic epidemiology study to compare epidemiological success, host factors, and drug resistance among the 4 major Mycobacterium tuberculosis (Mtb) lineages (L1-L4) circulating in Pune, India.

methodsWe performed whole-genome sequencing (WGS) of Mtb sputum culture-positive isolates from participants in two prospective cohort studies and predicted genotypic susceptibility using a validated random forest model. We compared lineage-specific phylogenetic and time-scaled metrics to assess epidemiological success.

resultsOf the 612 isolates that met sequence quality criteria, Most were L3 (44.6%). The majority (61.1%) of multidrug-resistant isolates were L2 (P < .001) and L2 demonstrated a higher rate and more recent resistance acquisition. L4 and/or L2 demonstrated higher clustering and time-scaled haplotypic density (THD) compared to L3 and/or L1, suggesting higher epidemiological success. L4 demonstrated higher THD and clustering (odds ratio, 5.1 [95% confidence interval, 2.3-12.3]) in multivariate models controlling for host factors and resistance.

conclusionsL2 shows a higher frequency of resistance, and both L2 and L4 demonstrate evidence of higher epidemiological success than L3 or L1 in Pune. Contact tracing around TB cases and heightened surveillance of TB DR in India is a public health priority.

Indexed as

Drug Resistance, Multiple, BacterialMycobacterium tuberculosisTuberculosisTuberculosis, Multidrug-ResistantAdultAntitubercular AgentsFemaleGenotypeHumansIndiaMaleMiddle AgedMolecular EpidemiologyPhylogenyProspective StudiesSputumAntitubercular Agentsdrug resistancelineagetransmissiontuberculosiswhole-genome sequencing

Identifiers

PMID38819323
PMCPMC11793027

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.